Literature DB >> 10367893

Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae.

R J Gilbert1, J L Jiménez, S Chen, I J Tickle, J Rossjohn, M Parker, P W Andrew, H R Saibil.   

Abstract

The human pathogen Streptococcus pneumoniae produces soluble pneumolysin monomers that bind host cell membranes to form ring-shaped, oligomeric pores. We have determined three-dimensional structures of a helical oligomer of pneumolysin and of a membrane-bound ring form by cryo-electron microscopy. Fitting the four domains from the crystal structure of the closely related perfringolysin reveals major domain rotations during pore assembly. Oligomerization results in the expulsion of domain 3 from its original position in the monomer. However, domain 3 reassociates with the other domains in the membrane pore form. The base of domain 4 contacts the bilayer, possibly along with an extension of domain 3. These results reveal a two-stage mechanism for pore formation by the cholesterol-binding toxins.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10367893     DOI: 10.1016/s0092-8674(00)80775-8

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  57 in total

1.  Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis.

Authors:  Johann S Braun; Jack E Sublett; Dorette Freyer; Tim J Mitchell; John L Cleveland; Elaine I Tuomanen; Joerg R Weber
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

2.  The solution structure and oligomerization behavior of two bacterial toxins: pneumolysin and perfringolysin O.

Authors:  Alexandra S Solovyova; Marcelo Nöllmann; Timothy J Mitchell; Olwyn Byron
Journal:  Biophys J       Date:  2004-07       Impact factor: 4.033

3.  Structure and functional characterization of Vibrio parahaemolyticus thermostable direct hemolysin.

Authors:  Itaru Yanagihara; Kumiko Nakahira; Tsutomu Yamane; Shuji Kaieda; Kouta Mayanagi; Daizo Hamada; Takashi Fukui; Kiyouhisa Ohnishi; Shin'ichiro Kajiyama; Toshiyuki Shimizu; Mamoru Sato; Takahisa Ikegami; Mitsunori Ikeguchi; Takeshi Honda; Hiroshi Hashimoto
Journal:  J Biol Chem       Date:  2010-03-24       Impact factor: 5.157

Review 4.  Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins.

Authors:  Rodney K Tweten
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Histone modifications induced by a family of bacterial toxins.

Authors:  Mélanie Anne Hamon; Eric Batsché; Béatrice Régnault; To Nam Tham; Stéphanie Seveau; Christian Muchardt; Pascale Cossart
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-03       Impact factor: 11.205

Review 6.  Listeria pathogenesis and molecular virulence determinants.

Authors:  J A Vázquez-Boland; M Kuhn; P Berche; T Chakraborty; G Domínguez-Bernal; W Goebel; B González-Zorn; J Wehland; J Kreft
Journal:  Clin Microbiol Rev       Date:  2001-07       Impact factor: 26.132

7.  Pneumolysin causes neuronal cell death through mitochondrial damage.

Authors:  Johann S Braun; Olaf Hoffmann; Miriam Schickhaus; Dorette Freyer; Emilie Dagand; Daniela Bermpohl; Tim J Mitchell; Ingo Bechmann; Joerg R Weber
Journal:  Infect Immun       Date:  2007-06-11       Impact factor: 3.441

8.  Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity.

Authors:  Glen C Ulett; Elisabeth E Adderson
Journal:  Curr Immunol Rev       Date:  2006-05

9.  Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines.

Authors:  Lea-Ann S Kirkham; Alison R Kerr; Gill R Douce; Gavin K Paterson; Deborah A Dilts; Dai-Fang Liu; Tim J Mitchell
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

10.  Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas.

Authors:  Guy Schoehn; Anne Marie Di Guilmi; David Lemaire; Ina Attree; Winfried Weissenhorn; Andréa Dessen
Journal:  EMBO J       Date:  2003-10-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.